Dose-Response Study of MR-107A-01 in The Treatment of Post-Surgical Dental Pain

Phase 2

Completed

• Conditions: Pain, Acute; Postoperative Pain; Pain
• Interventions: Drug: MR-107A-01; Drug: Placebo

• Registration Number: NCT04571515
• Lead Sponsor: Mylan Inc.

Brief Summary

MR-107A-01 is being studied to investigate its efficacy, safety, and dose-response after dental surgery.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2020-09-21
• Study First Submitted QC: 2020-09-25
• Study Start: 2020-09-29
• Study First Posted: 2020-10-01
• Primary Completion: 2020-12-15
• Study Completion: 2020-12-22
• Results First Submitted: 2022-04-07
• Status Verified: 2022-07
• Results First Submitted QC: 2022-07-12
• Last Update Submitted: 2022-07-12
• Results First Posted: 2022-08-08
• Last Update Posted: 2022-08-08

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 114

Inclusion Criteria

1. Males and females ≥18 years of age.
2. Requirement for dental surgery for extraction of ≥2 x third molars, at least 1 of which involves partial or complete mandibular bony impaction.
3. Pain Intensity (PI) using a Numeric Pain Rating Scale (NPRS) ≥5 during the 5 hours following the end of surgery.
4. Rating of moderate or severe pain on a 4-point categorical pain rating scale (i.e., none, mild, moderate, severe) during the 5 hours following the end of surgery.

Read More

Exclusion Criteria

1. Previously dosed with MR-107A-01.
2. Subject with known hypersensitivity to nonsteroidal antiinflammatory drugs (NSAIDs).
3. Active GI bleeding or a history of peptic ulcer disease, active inflammatory bowel disease, e.g., Crohn's Disease or ulcerative colitis, bleeding disorders that may affect coagulation.
4. Use of any investigational drug within 28 days, or 5 half-lives, prior to screening whichever is longer.
5. Use of medications with the potential to interact with MR-107A-01.
6. Other acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
MR-107A-01 10 mg twice in a 24-hour period	MR-107A-01	Oral tablet one day of dosing
MR-107A-01 15 mg once in a 24-hour period	MR-107A-01	Oral tablet one day of dosing
MR-107A-01 15 mg twice in a 24-hour period	MR-107A-01	Oral tablet one day of dosing
MR-107A-01 10 mg once in a 24-hour period	MR-107A-01	Oral tablet one day of dosing
Placebo twice in a 24-hour period	Placebo	Placebo tablet one day of dosing

Primary Outcome Measures

Name	Time	Method
Overall Summed Pain Intensity Difference (SPID)	24 hours after the first dose	Participants assessed Pain Intensity (PI) using a 0-10 numeric pain rating scale (NPRS) where 0 is no pain and 10 is worst pain imaginable. PI was assessed 17 times within 24 hours after the first study dose, and immediately before any rescue medication and/or at early termination. The participant's baseline PI was subtracted from the timepoint PI, to derive a Pain Intensity Difference (PID) for each timepoint. Overall Summed Pain Intensity Difference (SPID) measures pain intensity change relative to baseline over the 24 hour period after dosing, and corresponds to the Area Under the Curve (AUC) of the PID. In this study, higher positive Overall SPID indicates better pain improvement. Overall SPID could range from -120 to 240. Two hour windowed last observation carried forward was used as applicable where PI score obtained before a rescue medication replaced PI score for each timepoint within 2 hours following rescue dose.

Secondary Outcome Measures

Name	Time	Method
Rescue Medication Use	24 hours after the first dose	Number of rescue medication doses
Total Pain Relief	24 hours after the first dose	Pain relief was assessed by participants using a 5 point scale, where 0 = none, 1 = slight, 2 = moderate, 3 = good or a lot, and 4 = complete. Pain relief was measured 17 times within 24 hours after the first study medication dose, and immediately before any rescue medication and/or at the time of early termination. Two-hour windowed last observation carried forward approach was used whereby the pain relief score obtained before a given rescue medication was carried forward to replace the pain relief scores collected at each observation timepoint within 2 hours following the rescue dose. Total pain relief (TOTPAR) had Areas Under the Curve (AUCs) calculated for each time point. The range for 24 hours post dose TOTPAR AUC was 0 to 96. Higher positive values indicate a better outcome with larger pain improvements.
Patient's Global Assessment of Pain Control	24 hours after the first dose	5 point scale, where 0 is poor, 1 is fair, 2 is good, 3 is very good, and 4 is excellent Responder = 2 is good, 3 is very good, and 4 is excellent, Non-responder = 1 is fair, 0 is poor, and missing values
Pain Intensity Using a Numeric Pain Rating Scale Utilizing 2-hour Windowed Last Observation Carried Forward (W2LOCF)	24 hours after the first dose	10 point scale, where 0 is no pain and 10 is the worst pain imaginable; 2-hour windowed last observation carried forward (W2LOCF) utilizes "pain right now" just prior to rescue medication use and censors subsequent pain intensity values for 2 hours when calculating SPIDs
Pain Relief: Number and Percentage of Subjects With Perceptible and Meaningful Pain Relief	24 hours after the first dose	The time to onset of first perceptible relief was defined as the post dose time at which the subject first begins to feel pain relief. The time to meaningful pain relief was defined as the post dose time at which the subject begins to feel meaningful pain relief. The assessments of perceptible and meaningful pain relief were ceased when rescue medication was taken.

Trial Locations

Locations (1)

Research Facility 101; 🇺🇸 Salt Lake City, Utah, United States